Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.44 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.44 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.44 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.34 |
| ▸ | DUT | P33316 | 2/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL51723 | 0.84 | SLC28A1 (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL28786348 | 0.84 | SLC28A1 (0.45) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL27451524 | 0.82 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL2242410 | 0.82 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL249822 | 0.82 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL27703606 | 0.82 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL65485 | 0.82 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL414705 | 0.82 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| Hydrochloric Acid SCHEMBL27782735 | 0.82 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 | |
| SCHEMBL438241 | 0.82 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114126668-A | Compositions and methods for the treatment of hemochromatosis | 超基因制药股份有限公司 | 2022-03-01 | — | — | CN | claimed |
| EP-1493818-A2 | Nucleoside triphosphates and their incorporation into ribozymes | RIBOZYME PHARMACEUTICALS, INC. (US) | 2005-01-05 | — | — | EP | claimed |
| US-6509460-B1 | Contacting the modified nucleotide triphosphate with a mixture comprising a nucleic acid template, an RNA polymerase enzyme, and an enhancer of modified nucleotide triphosphate incorporation | RIBOZYME PHARMACEUTICALS, INC. | 2003-01-21 | — | — | US | claimed |
| US-6127535-A | FOR THE INCORPORATION OF MODIFIED (NON-STANDARD) AND UNMODIFIED NUCLEOTIDES INTO NUCLEIC ACIDS | RIBOZYME PHARMACEUTICALS, INC. (US) | 2000-10-03 | — | — | US | claimed |
| EP-4713450-A1 | ENGINEERED CONSTRUCTS WITH CASSETTE ARRANGEMENTS FOR INCREASED TRANSCRIPTION OF RNA PAYLOADS | Shape Therapeutics Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4580609-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | Rejuvenation Technologies Inc. (US) | 2025-07-09 | — | — | EP | disclosed |
| CN-119789852-A | Compositions and methods for delivering RNA | 再生技术有限责任公司 | 2025-04-08 | — | — | CN | disclosed |
| WO-2025049632-A1 | COMPOSITIONS AND METHODS FOR BROAD DELIVERY OF RNA TO TISSUE | REJUVENATION TECHNOLOGIES INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| CN-119317714-A | Nucleic acid modified biological cells with amplification-dependent gene expression | 蒂宾根大学医学院 | 2025-01-14 | — | — | CN | disclosed |
| EP-4479406-A1 | OXAZINE DYES AND THEIR USE IN NUCLEIC ACID AMPLIFICATION REACTIONS | Promega Corporation (US) | 2024-12-25 | — | — | EP | disclosed |
| CN-112805386-B | Plasmid containing a sequence encoding mRNA having a segmented poly (A) tail | 埃泽瑞斯公司 | 2024-12-03 | — | — | CN | disclosed |
| WO-2024238584-A1 | ENGINEERED CONSTRUCTS WITH CASSETTE ARRANGEMENTS FOR INCREASED TRANSCRIPTION OF RNA PAYLOADS | SHAPE THERAPEUTICS INC. (US) | 2024-11-21 | — | — | WO | disclosed |
| WO-2011069587-A1 | LYOPHILIZATION OF NUCLEIC ACIDS IN LACTATE-CONTAINING SOLUTIONS | CUREVAC GMBH (DE) | 2011-06-16 | — | — | WO | disclosed |
| WO-2007016455-A2 | COMPOSITIONS AND METHODS USING AMINOGLYCOSIDES TO BIND DNA AND RNA | CLEMSON UNIVERSITY RESEARCH FOUNDATION (US) | 2007-02-08 | — | — | WO | disclosed |
| EP-1212416-A2 | NUCLEIC ACID BASED MODULATORS OF GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001016312-A2 | NUCLEIC ACID BASED MODULATORS OF GENE EXPRESSION | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
| EP-1073732-A2 | NUCLEOSIDE TRIPHOSPHATES AND THEIR INCORPORATION INTO RIBOZYMES | RIBOZYME PHARMACEUTICALS, INC. (US) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999055857-A2 | NUCLEOSIDE TRIPHOSPHATES AND THEIR INCORPORATION INTO RIBOZYMES | RIBOZYME PHARMACEUTICALS, INC. (US) | 1999-11-04 | — | — | WO | disclosed |
| US-5902879-A | Methoxyoxalamido and succinimido precursors for nucleophilic addition to nucleosides, nucleotides and oligonucleotides | FIDELITY SYSTEMS, INC. (US) | 1999-05-11 | — | — | US | disclosed |
| WO-1998050530-A9 | ENZYMATIC NUCLEIC ACIDS: SYNTHESIS, SELECTION AND USE | RIBOZYME PHARM INC (US) | 1999-03-25 | — | — | WO | disclosed |